Table 3.

Effects of erlotinib and/or naproxen in the prevention of bladder cancer when agents were started 1 week after final OH-BBN treatment.

Urinary bladder cancers
GroupNumber of ratsCarcinogenTreatmentIncidenceMultiplicityWeight (mg)Number greater than 200 mg
125OH-BBNErlotinib, 42 mg/kg BW, 1×/week76% (24%↓)1.48 (47%↓)b272 (8%↓)a,c35% (40%↓)
225OH-BBNNaproxen, 30 mg/kg BW/day (3 weeks on / 3 weeks off)72% (28%↓)a1.20 (57%↓)b213 (28%↓)a,c39% (33%↓)c
324OH-BBNErlotinib + Naproxen (as indicated for groups 1 and 2)58% (42%↓)b0.96 (66%↓)b136 (54%↓)b9% (84%↓)b
423OH-BBNNone100%2.7929558%
  • Note: Female Fischer-344 rats received OH-BBN for 8 weeks beginning at 56 days of age. Administration of Erlotinib and/or Naproxen initiated 1 week after final OH-BBN treatment. Study terminated 10 months after the initial OH-BBN treatment.

  • aStatistically significant from the control group (group 4) at P ≤ 0.05.

  • bStatistically significant from the control group (group 4) at P ≤ 0.01.

  • cStatistically significant from the combination group (group 3) at P ≤ 0.05.